Revolution Medicines has recently announced interim analysis results from its Phase III RASolute 302 trial evaluating the investigational oral RAS(ON) inhibitor Daraxonrasib (RMC-6236), marking a significant advance in the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC), a disease that has long lacked meaningful therapeutic breakthroughs.

Pancreatic cancer is often referred to as the “king of cancers” due to its extremely poor prognosis, particularly in advanced stages where treatment has historically relied heavily on chemotherapy. While immunotherapies have achieved major success in other cancers such as lung cancer and melanoma, they have not yet produced comparable breakthroughs in PDAC. In this study, Daraxonrasib demonstrated a substantial survival benefit in previously treated second-line metastatic PDAC patients. In the intent-to-treat population, median overall survival reached 13.2 months, compared with 6.7 months in the chemotherapy control arm, representing approximately a 60% reduction in the risk of death (hazard ratio ~0.40), with highly statistically significant differences.

The study is a global, multicenter, randomized Phase III clinical trial enrolling approximately 460–500 patients. It compares once-daily oral Daraxonrasib (300 mg monotherapy) against investigator’s choice of standard intravenous chemotherapy. In addition to overall survival, progression-free survival also showed clear improvement. In terms of safety, the drug was generally well tolerated, with no new safety signals observed, suggesting potential for sustained use in advanced patients.

Daraxonrasib is a next-generation, multi-selective, non-covalent RAS(ON) inhibitor. Its mechanism of action involves suppressing active-state RAS proteins and blocking downstream signaling pathways, thereby inhibiting tumor growth. Unlike traditional KRAS G12C inhibitors, Daraxonrasib operates by binding to an intracellular chaperone protein and “anchoring” active RAS, enabling broader coverage across multiple RAS mutations, including common PDAC-associated variants such as G12D and G12V, and potentially even non-mutant RAS signaling.

From a cancer biology perspective, RAS mutations are among the most prevalent oncogenic drivers across human cancers, and pancreatic cancer is particularly dependent on RAS signaling, with approximately 85%–90% of cases harboring RAS alterations. Historically, RAS was considered “undruggable” due to its structural characteristics, placing it outside the reach of conventional targeted therapies. Although the development of KRAS G12C inhibitors represented a major milestone, their durability of response and overall survival benefits have remained limited.

The positive Phase III results of Daraxonrasib are therefore viewed as potentially practice-changing. The company stated that these data will support accelerated submissions to regulatory authorities, including the U.S. Food and Drug Administration (FDA), and may benefit from priority review pathways that could shorten approval timelines. Based on current progress, the likelihood of approval in the second-line setting has increased significantly, with potential expansion into first-line therapy in the future.

Experts in the field note that, if confirmed by full datasets, these findings may mark the beginning of a new era of precision oncology in pancreatic cancer centered on the RAS pathway, potentially shifting treatment away from decades-long chemotherapy dominance and establishing a new backbone therapeutic option for this highly aggressive malignancy.

The compound patent for Daraxonrasib was filed under PCT application WO2022060836A1 and has entered approximately 25 jurisdictions, including China, the United States, the European Union, Japan, South Korea, Australia, and Canada. It has been granted in several major markets, including China (CN120794999B), the United States, and Japan. The application date is September 15, 2021, with an estimated expiration date of September 15, 2041. Given its broad global grant coverage, the patent is considered to have strong inventive merit and relatively stable protection, with approximately 15 years of market exclusivity remaining. Following the release of the Phase III results, Revolution Medicines’ stock surged 34% in pre-market trading, bringing its market capitalization to approximately $25.7 billion.